Next Article in Journal
Contrast-Enhanced Ultrasound (CEUS) for Follow-Up of Bosniak 2F Complex Renal Cystic Lesions—A 12-Year Retrospective Study in a Specialized European Center
Next Article in Special Issue
The CXCR4-Dependent LASP1-Ago2 Interaction in Triple-Negative Breast Cancer
Previous Article in Journal
Genetic Engineering of Zebrafish in Cancer Research
Previous Article in Special Issue
Effects of Cancer Stem Cells in Triple-Negative Breast Cancer and Brain Metastasis: Challenges and Solutions
Open AccessArticle

Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells

1
Department of Cancer Biology, University of Toledo Health Science Campus, Toledo, OH 43614, USA
2
Department of Pharmacology & Experimental Therapeutics, College of Pharmacy & Pharmaceutical Sciences, University of Toledo Main Campus, Toledo, OH 43606, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(8), 2169; https://doi.org/10.3390/cancers12082169
Received: 30 June 2020 / Revised: 23 July 2020 / Accepted: 2 August 2020 / Published: 4 August 2020
The eukaryotic translation initiation factor 4F complex (eIF4F) is a potential chemotherapeutic target in triple-negative breast cancer (TNBC). This complex regulates cap-dependent translational initiation and consists of three core proteins: eIF4E, eIF4G, and eIF4A1. In this study, we focus on repositioning compounds as novel inhibitors of eIF4A1-mediated translation. In order to accomplish this goal, a modified synthetic reporter assay was established. More specifically, a (CGG)4 motif, which confers eIF4A dependency, was incorporated into the 5’-leader region of a luciferase-tdTomato lentiviral reporter construct. The Prestwick Chemical Library was then screened in multiple TNBC cell lines by measuring the tdTomato fluorescent intensity. We identified several cardiac glycosides as potential inhibitors of eIF4A1-mediated translation. Based on our studies, we find that cardiac glycosides inhibit the expression of eIF4A1. To identify a potential mechanism by which this was occurring, we utilized the Integrative Library of Integrated Network-Based Cellular Signatures (iLINCS). Our pursuits led us to the discovery that cardiac glycosides also decrease levels of c-MYC. Quantitative PCR confirmed that decreases in c-MYC and eIF4A were occurring at the transcriptional level. As such, disruption of the eIF4A1-c-MYC axis may be a viable approach in the treatment of TNBC. The novel combination of rocaglamide A and digoxin exhibited synergistic anti-cancer activity against TNBC cells in vitro. The findings in this study and others are important for formulating potential combination chemotherapies against eIF4A1 in vivo. Thus, drug repositioning may be one classical approach to successfully target eIF4A1 in TNBC patients. View Full-Text
Keywords: eIF4A1; c-MYC; digoxin; bufalin; rocaglamide A; TNBC; repurposing; repositioning eIF4A1; c-MYC; digoxin; bufalin; rocaglamide A; TNBC; repurposing; repositioning
Show Figures

Graphical abstract

MDPI and ACS Style

Howard, C.M.; Estrada, M.; Terrero, D.; Tiwari, A.K.; Raman, D. Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells. Cancers 2020, 12, 2169.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop